Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome

Autor:	S J Middleton, N L Meyers, R M J Palmer, Hubert Piessevaux, M C Horne, Jan Tack, J S Bloor
Rok vydání:	2006
Předmět:	Adult Male Abdominal pain medicine.medical_specialty Constipation Pilot Projects Placebo Gastroenterology Descending colon Irritable Bowel Syndrome Internal medicine Humans Medicine Ascending colon Single-Blind Method Pharmacology (medical) Irritable bowel syndrome Dose-Response Relationship Drug Hepatology business.industry Stomach Middle Aged Bridged Bicyclo Compounds Heterocyclic medicine.disease Renzapride Treatment Outcome medicine.anatomical_structure Benzamides Female Serotonin Antagonists medicine.symptom Gastrointestinal Motility business medicine.drug
Zdroj:	Alimentary Pharmacology and Therapeutics. 23:1655-1665
ISSN:	1365-2036 0269-2813
Popis:	Aim To investigate the efficacy and safety of renzapride, a potent 5-hydroxytryptamine type-4 receptor full agonist and 5-hydroxytryptamine type-3 receptor antagonist in patients with constipation-predominant irritable bowel syndrome. Methods In this dose-escalating pilot study, 17 patients with constipation-predominant irritable bowel syndrome received placebo, renzapride 2 mg o.d. and renzapride 2 mg b.d. sequentially for 28 days. Response was determined by radio-opaque marker measurement of overall gastrointestinal and segmental colonic transit and patients' assessment of their irritable bowel syndrome symptoms. Results Renzapride reduced mean overall gastrointestinal transit time (placebo, 2.9 +/- 1.6 days; renzapride 2 mg o.d., 2.6 +/- 1.4 days; renzapride 2 mg b.d., 1.9 +/- 1.6 days) (P = 0.024) and accelerated segmental colonic transit, with statistically significant differences for renzapride 2 mg b.d. over placebo in caecum/ascending colon (P = 0.019) and descending colon (P = 0.022). Renzapride also reduced abdominal pain, increased the number of pain-free days and improved stool consistency. The frequency of reported adverse events was similar on renzapride and placebo. Conclusions Renzapride is well-tolerated, stimulates gastrointestinal transit and improves symptoms in patients with constipation-predominant irritable bowel syndrome, particularly at the 2 mg b.d. dose, where improvements in gastrointestinal symptoms were evident over placebo. This study has established proof of concept and supports further investigation of renzapride in patients with constipation-predominant irritable bowel syndrome.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::893be7ad783a178d0fb66c161b7d7dea https://doi.org/10.1111/j.1365-2036.2006.02940.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.